🔍

SAILIFE - Sai Life

📊 NSE: SAILIFE 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 12:38

📢 Recent Corporate Announcements

Sai Life Sciences Receives GST Demand Order of INR 32.86 Crore

🔴 NEGATIVE ⭐ 6/10

REGULATORY 📅 30 Apr 2026, 08:35 AM

Sai Life Sciences Limited has received an order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi, regarding GST discrepancies for the financial year 2021-22. The total demand amounts to INR 32.86 crore, which includes IGST, interest, and penalties. The issue stems from alleged excess Input Tax Credit (ITC) claims in GSTR-3B compared to GSTR-2A. The company has stated it will file an appeal at the Tribunal level and does not expect a material financial impact.

Total tax demand of INR 32.86 crore issued by Karnataka tax authorities
Demand includes IGST of INR 16.28 crore and interest of INR 13.32 crore
Penalty of INR 3.26 crore imposed for alleged excess ITC claims in FY 2021-22
Company intends to contest the order by filing an appeal with the Tribunal

💡 Investors should monitor the outcome of the upcoming appeal as the demand represents a significant one-time liability. While the company expects a favorable outcome, any adverse ruling at the Tribunal level could impact short-term cash flows.

Sai Life Sciences Allots 2.44 Lakh Equity Shares Under ESOP Schemes

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Apr 2026, 09:35 PM

Sai Life Sciences has allotted 2,44,281 equity shares of Re. 1 each following the exercise of options under its 2008 and 2018 ESOP plans. The allotment includes 44,500 shares at an exercise price of Rs. 188.90 and 1,99,781 shares at Rs. 127.30. This corporate action has resulted in a total capital realization of approximately Rs. 3.38 crore for the company. Consequently, the total paid-up share capital has increased to 21,20,23,515 equity shares.

Allotment of 2,44,281 equity shares of face value Re. 1 each upon exercise of options.
Realized total funds amounting to INR 3,38,38,171.30 from the exercise of options.
Total issued share capital increased to 21,20,23,515 shares post-allotment.
Exercise prices set at Rs. 188.90 for ESOP 2008 and Rs. 127.30 for MESOP 2018.

💡 No immediate action is required as this is a routine allotment with minimal equity dilution. Investors should monitor the overall trend of ESOP issuances to assess long-term dilution impact.

Sai Life Sciences Submits SEBI Compliance Certificate for Quarter Ended March 31, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Apr 2026, 04:27 PM

Sai Life Sciences Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited, confirms that the details of securities dematerialized or rematerialized during the quarter ended March 31, 2026, have been furnished to the stock exchanges. This is a standard procedural filing required by all listed entities to maintain transparency in shareholding records. The filing indicates that the company is in compliance with its routine regulatory obligations.

Compliance certificate submitted for the quarter ended March 31, 2026
Confirmation received from Registrar and Share Transfer Agent (RTA) KFin Technologies Limited
Adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Details of dematerialized/rematerialized securities furnished to both BSE and NSE

💡 No action is required as this is a routine regulatory filing. Investors should monitor the company's upcoming quarterly financial results for fundamental performance indicators.

Sai Life Sciences Appoints Dr. John Pavey as Head of Global PR&D Effective April 1, 2026

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 30 Mar 2026, 10:25 PM

Sai Life Sciences has announced a planned leadership transition within its Senior Management Personnel. Dr. John Pavey will take over as Head of Global Process Research and Development (PR&D) effective April 1, 2026, succeeding Dr. Dean David Edney who retires on March 31, 2026. Dr. Pavey brings over 20 years of global experience from top-tier pharmaceutical companies including Johnson & Johnson and AstraZeneca. This move ensures continuity in the company's critical R&D functions with a highly experienced industry veteran.

Dr. John Pavey appointed as Senior Management Personnel (SMP) effective April 1, 2026
Dr. Dean David Edney to retire from the Head of Global PR&D role on March 31, 2026
Incoming leader Dr. Pavey has over 20 years of experience in CMC and chemical development
Dr. Pavey's career includes senior roles at Johnson & Johnson, UCB, and AstraZeneca
Transition focuses on maintaining expertise in API development, regulatory approvals, and sustainable manufacturing

💡 This is a routine management succession and should be viewed as a neutral event. Investors should monitor if the new leadership brings any strategic shifts to the company's R&D service offerings.

Sai Life Sciences to Close Trading Window from April 1 for Q4 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Mar 2026, 03:06 PM

Sai Life Sciences Limited has announced the closure of its trading window starting April 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is a standard procedure ahead of the declaration of the audited financial results for the fourth quarter and the full financial year ending March 31, 2026. The window applies to all designated persons and their immediate relatives, prohibiting them from trading in the company's securities. The window will reopen 48 hours after the financial results are officially made public.

Trading window closure begins on Wednesday, April 1, 2026.
Closure is in relation to the Audited Financial Results for Q4 and FY ending March 31, 2026.
The window will remain closed until 48 hours after the results are declared.
The specific date for the Board Meeting to approve results will be announced later.

💡 This is a routine regulatory filing and requires no action from general investors. Monitor future announcements for the specific date of the Q4 earnings release to assess the company's financial performance.

Sai Life Sciences Allots 11,100 Equity Shares Under ESOP 2008

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Mar 2026, 01:00 PM

Sai Life Sciences Limited has allotted 11,100 equity shares of face value Re. 1 each to employees under its ESOP 2008 scheme. The options were exercised at a price of Rs. 188.90 per share, leading to a total realization of INR 20.97 lakhs for the company. This allotment increases the company's total issued share capital to 211,779,234 shares. The dilution caused by this specific allotment is minimal and part of standard employee compensation practices.

11,100 equity shares allotted upon exercise of options under ESOP 2008
Exercise price of Rs. 188.90 per share realized a total of INR 20,96,790
Total issued share capital post-allotment stands at 211,779,234 shares
The allotment was approved via circular resolution dated March 24, 2026

💡 No action is required as this is a routine ESOP allotment with negligible impact on share value or ownership structure.

Sai Life Sciences Receives ₹4.54 Cr Income Tax Demand for TDS Non-Deduction

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 21 Mar 2026, 12:01 PM

Sai Life Sciences Limited has received an order from the Deputy Commissioner of Income Tax (International Taxation), Hyderabad, regarding the non-deduction of TDS on payments made to non-residents for the assessment year 2020-21. The total demand raised is approximately ₹4.54 crore, which includes a tax component of ₹2.54 crore and interest of ₹1.99 crore. The company has stated its intention to file an appeal against this order at the appellate level. Management currently expects a favorable outcome and does not anticipate a material financial impact on the company's operations.

Tax demand of ₹2,54,39,944 raised under Section 201(1) of the Income Tax Act, 1961.
Interest of ₹1,99,17,238 levied for non-deduction of TDS for AY 2020-21.
Total quantifiable financial implication currently stands at ₹4,53,57,182.
Company plans to challenge the order through an appeal, citing no expected material impact.
Additional penalties may be assessed and levied by the tax officer at a later stage.

💡 Investors should view this as a routine tax litigation matter that is unlikely to impact the company's core fundamentals. No immediate action is required, but the outcome of the appeal should be monitored in future disclosures.

Sai Life Sciences to Attend Investec CDMO Day on March 13, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 07 Mar 2026, 11:08 AM

Sai Life Sciences Limited has scheduled a group meeting with Investec Capital Services (India) for their 'CDMO Day' on March 13, 2026. The meeting will be held in Hyderabad and involves interactions with institutional investors and analysts. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be discussed during the session. Furthermore, no new investor presentation will be introduced during this specific event.

Meeting scheduled for March 13, 2026, in Hyderabad.
Participation in the Investec Capital Services (India) CDMO Day event.
Format of the interaction is a group meeting with analysts and investors.
Company confirmed that no new presentation or UPSI will be shared.

💡 This is a routine investor relations event; shareholders should monitor for any post-event disclosures, though no major immediate impact is expected.

ICRA Assigns [ICRA]AA (Stable) and [ICRA]A1+ Ratings to Sai Life Sciences' Rs 768.60 Cr Debt

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 26 Feb 2026, 05:12 PM

ICRA Limited has assigned high-grade credit ratings to Sai Life Sciences Limited for its total debt facilities of Rs 768.60 crore. The long-term fund-based facilities of Rs 550 crore received an [ICRA]AA (Stable) rating, while short-term non-fund-based facilities of Rs 218.60 crore were assigned [ICRA]A1+. These ratings reflect a strong credit profile and a high degree of safety regarding the timely servicing of financial obligations. The facilities are spread across major lenders including State Bank of India, IndusInd Bank, and Bank of Baroda.

Assigned [ICRA]AA (Stable) rating for Rs 550.00 crore long-term fund-based facilities
Assigned [ICRA]A1+ rating for Rs 218.60 crore short-term non-fund-based facilities
Total rated debt instruments amount to Rs 768.60 crore across multiple banking partners
State Bank of India holds the largest share of rated limits at Rs 230.60 crore
The 'Stable' outlook indicates ICRA's expectation of maintained credit quality in the medium term

💡 Investors should view these high investment-grade ratings as a sign of financial robustness and low credit risk. No immediate action is required, but the ratings support a positive long-term outlook for the company's capital structure.

Sai Life Sciences Allots 1.39 Lakh Equity Shares Under ESOP and MESOP Schemes

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Feb 2026, 03:58 PM

Sai Life Sciences Limited has issued a revised intimation regarding the allotment of 1,39,007 equity shares under its ESOP 2008 and MESOP 2018 plans. The revision corrects a previous omission of 10,000 shares in the earlier filing dated February 23, 2026. The company realized a total of INR 1.22 crore from the exercise of these options at various price points ranging from Rs. 23.30 to Rs. 188.90. Post-allotment, the total issued share capital of the company stands at 21,17,68,134 shares.

Total allotment of 1,39,007 equity shares of Re 1 face value each following option exercises.
Exercise prices for the shares were set at Rs. 23.30, Rs. 127.30, and Rs. 188.90 per share.
The company realized a total amount of INR 1,22,02,422.30 from the exercise of these options.
Total issued share capital has increased to 21,17,68,134 equity shares following this allotment.

💡 No action is required as this is a routine allotment of shares to employees. Investors should simply note the marginal increase in the total share count and potential minor dilution.

Sai Life Sciences Allots 1.29 Lakh Equity Shares Under ESOP Schemes

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Feb 2026, 12:31 PM

Sai Life Sciences Limited has allotted 1,29,007 equity shares of Re. 1 each to employees upon the exercise of stock options. The allotment comprises 19,007 shares under the ESOP 2008 scheme and 1,10,000 shares under the Management ESOP Plan 2018. The company realized a total of approximately Rs. 1.03 crore from these exercises. This move increases the total issued share capital to 21,17,58,134 equity shares.

Allotment of 1,29,007 equity shares following the exercise of employee stock options
Total funds realized by the company from the exercise amount to Rs. 1,03,13,422.30
Exercise prices varied between Rs. 23.30, Rs. 127.30, and Rs. 188.90 per share across different schemes
Total paid-up equity capital increased to 21,17,58,134 shares post-allotment

💡 This is a routine corporate action related to employee compensation and has no immediate impact on company fundamentals. Investors should simply note the minor equity dilution resulting from the increased share count.

Sai Life Sciences to Meet Investors at Kotak and IIFL Conferences on Feb 25-26

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Feb 2026, 03:55 PM

Sai Life Sciences Limited has scheduled meetings with institutional investors and analysts in Mumbai. The company will participate in the Kotak - Chasing Growth 2026 conference on February 25 and the IIFL 17th Entrepreneurial India Conference on February 26, 2026. These interactions will be conducted in one-on-one or group formats. The company has clarified that no unpublished price sensitive information will be shared and no new presentations will be used during these sessions.

Participation in Kotak - Chasing Growth 2026 conference on February 25, 2026.
Participation in IIFL 17th Entrepreneurial India Conference on February 26, 2026.
Meetings scheduled in Mumbai via one-on-one and group interaction formats.
Company confirmed no new presentations or unpublished price sensitive information will be disclosed.

💡 This is a routine investor engagement activity; investors should monitor for any qualitative management commentary that may emerge from these institutional interactions.

Sai Life Sciences Releases Q3 FY26 Earnings Call Transcript

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 13 Feb 2026, 02:22 PM

Sai Life Sciences has officially released the transcript for its earnings call held on February 6, 2026. The call discussed the company's unaudited financial performance for the quarter and nine-month period ending December 31, 2025. This disclosure is part of the mandatory regulatory requirements under SEBI (LODR) Regulations, 2015. The transcript provides detailed management commentary and responses to institutional investor queries regarding the company's operational trajectory.

Earnings call transcript for Q3 FY26 and 9M FY26 now available for public review
The call was originally conducted on February 6, 2026, at 4:00 PM IST
Filing complies with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Transcript includes detailed discussions on financial results for the period ended December 31, 2025

💡 Investors should read the transcript to gain insights into management's outlook on the CDMO sector and specific growth drivers for the upcoming fiscal year. It is a vital document for understanding the qualitative aspects of the recent financial results.

Sai Life Sciences Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 06 Feb 2026, 06:41 PM

Sai Life Sciences Limited has released the audio recording of its earnings call held on February 6, 2026. The call addressed the company's unaudited financial performance for the third quarter and the nine-month period ending December 31, 2025. This disclosure is part of the company's regulatory compliance under SEBI (LODR) Regulations, 2015. Investors can access the recording on the company's website to hear management's detailed commentary on operational results and future outlook.

Earnings call conducted on February 6, 2026, at 4:00 PM IST.
Focuses on unaudited financial results for Q3 and the nine months ended December 31, 2025.
Audio recording link provided in compliance with SEBI (LODR) Regulation 30.
Recording is publicly accessible via the company's official website link.

💡 Investors should listen to the recording to understand management's perspective on the company's financial health and strategic direction for the upcoming quarters.

Sai Life Sciences Q3 FY26 PAT Surges 86% to ₹100 Cr; EBITDA Margins Expand to 34.4%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 02:59 PM

Sai Life Sciences reported a strong performance for Q3 FY26, with consolidated revenue growing 27% YoY to ₹556 crore. The company's profitability saw a significant boost as EBITDA rose 54% to ₹191 crore, driven by a 605 bps margin expansion to 34.4%. For the nine-month period, PAT grew by a massive 199% to ₹245 crore, reflecting robust operational leverage and healthy demand in the CDMO segment. The company is aggressively investing in capacity, with ₹405 crore of the planned ₹700 crore FY26 capex already deployed.

Q3 FY26 Revenue increased 27% YoY to ₹556 crore, with CDMO services contributing 65% of total revenue.
EBITDA margins expanded significantly by 605 bps to 34.4%, outperforming the company's long-term guidance of 28-30%.
Net Profit (PAT) for the quarter jumped 86% YoY to ₹100 crore, while 9M FY26 PAT grew 199% to ₹245 crore.
Added 7 molecules to the late-phase and commercial pipeline during the year, taking the total to 43 molecules.
Invested ₹405 crore in capital expenditure out of a ₹700 crore plan for FY26 to expand manufacturing capacity by ~450KL.

💡 Investors should monitor the company's execution of its ₹700 crore capex plan and its ability to maintain margins above 30% as new capacities come online. The strong pipeline growth in late-phase molecules provides good revenue visibility for the coming years.

View All SAILIFE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In H1 FY26, the CDMO segment grew 72% YoY to INR 667 Cr, contributing 64% of total revenue. The CRO segment grew 28% YoY to INR 367 Cr, contributing 36% of total revenue. For the full FY 2024-25, total income grew 15.9% YoY to INR 1,731.35 Cr.

Geographic Revenue Split

The company serves 300+ global clients across the US, UK, EU, and Japan, though specific percentage splits per region are not disclosed in the available documents.

Profitability Margins

Gross margins expanded in FY25 due to operational efficiencies in commercial products. PAT margin expanded 430 bps to 10.0% in FY25 (INR 170.13 Cr) from 5.7% in FY24. In H1 FY26, PAT stood at INR 144 Cr.

EBITDA Margin

EBITDA margin was 25.0% in FY25 (INR 424.74 Cr), up 460 bps from 20.4% in FY24. Margins further improved to 27% in H1 FY26 and reached 29% (INR 156 Cr) in Q2 FY26 due to operating leverage and better capacity utilization.

Capital Expenditure

The company incurred INR 248 Cr in capex during H1 FY26, primarily for R&D capacity expansion, against a total planned capex of INR 700 Cr for the full FY26.

Credit Rating & Borrowing

Finance costs decreased by 11.3% YoY to INR 76.16 Cr in FY25, primarily driven by the repayment of INR 720 Cr of debt using IPO proceeds.

⚙️ Operational Drivers

Raw Materials

Specific chemical names are not disclosed; however, Cost of Goods Sold (COGS) represented 26.9% of total income in FY25, amounting to INR 465.76 Cr.

Capacity Expansion

The company is expanding R&D capacity and advancing offerings in new modalities. Current capacity utilization was reported at 67% for FY 2024-25.

Raw Material Costs

COGS increased by 4.5% YoY to INR 465.76 Cr in FY25, a slower rate than revenue growth, leading to a 290 bps increase in gross margins due to operational efficiencies in commercial products.

Manufacturing Efficiency

Capacity utilization stood at 67% in FY25. Efficiency gains in commercial product manufacturing were cited as the primary driver for gross margin expansion.

📈 Strategic Growth

Expected Growth Rate

15-20%

Growth Strategy

Growth is driven by an integrated CRDMO model that provides seamless support from discovery to commercial manufacturing. The strategy includes scaling late-stage and commercial programs (3 products recently moved to late-stage) and investing INR 700 Cr in FY26 for R&D and new technology capacity.

Products & Services

The company provides CRO (Discovery) and CDMO (Development and Manufacturing) services, including CMC (Chemistry, Manufacturing, and Controls) and integrated drug discovery services.

Brand Portfolio

Sai Life Sciences

New Products/Services

The company is advancing offerings in new modalities and technologies; 3 products recently transitioned into the late-stage pipeline, which typically drives higher revenue as they move toward commercialization.

Market Expansion

Expansion is focused on global pharma hubs in the US, UK, EU, and Japan, leveraging world-class facilities in Hyderabad, Bidar, and Manchester.

Strategic Alliances

Maintains a 5-year strategic partnership with Schrödinger (signed in 2023) focused on drug discovery candidates.

🌍 External Factors

Industry Trends

The industry is seeing a continued shift toward outsourcing by global pharma to integrated CRDMOs. Sai Life Sciences is positioning itself to capture this by expanding its late-stage pipeline and R&D capabilities.

Competitive Landscape

Competes with global CRDMOs; the company uses top-tier consulting firms to benchmark its productivity and cost structure against global peers.

Competitive Moat

The moat is built on 25+ years of expertise, an integrated 'Discovery to Delivery' model, and deep-rooted relationships with 18 of the top 25 global pharma firms, which creates high switching costs.

Macro Economic Sensitivity

The business is sensitive to global pharmaceutical R&D spending and macroeconomic trends affecting biotech venture capital funding.

Geopolitical Risks

Operations across India and the UK expose the company to international regulatory shifts and trade policies in the pharma sector.

⚖️ Regulatory & Governance

Industry Regulations

The company maintains cost records as mandated under Section 148(1) of the Companies Act, 2013. It must comply with stringent manufacturing standards for global pharma supply.

Taxation Policy Impact

The consolidated effective tax rate for FY 2024-25 was 25.3%, with a total tax expense of INR 57.57 Cr.

Legal Contingencies

An order was passed under Section 73(9) of the Goods and Services Tax Act by the Deputy Commissioner of Commercial Taxes (Audit), Bidar, regarding tax matters.

⚠️ Risk Analysis

Key Uncertainties

Biotech funding volatility poses a risk to the CRO segment's growth. Operational risks are managed through a Vigil Mechanism and a Code of Conduct for Board and Senior Management.